Mini-Reviews in Medicinal Chemistry · 2013 · 10 citations · 10 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoverySignal TransductionEnzyme InhibitionEnzyme TargetsMolecular DockingProtein PhosphorylationTyrosine Kinase InhibitorsVirtual ScreeningActive Site ResiduesPhosphatase InhibitionPhosphatase TargetsProtein Tyrosine Phosphatase InhibitorsSelective Tyrosine Kinase InhibitorsTherapeutic Target IdentificationTherapeutic Target ValidationVirtual Screening Validation
Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
10
Lori D. Klaman, Olivier Boss, Odile D. Peroni et al. · Molecular and Cellular Biology · 2000 · 1.2K citations
Wei Zhang, Di Hong, Yueyang Zhou et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 2006 · 266 citations
Structure Determination of T Cell Protein-tyrosine Phosphatase
Lars Iversen, Karin Möller, Anja K. Pedersen et al. · Journal of Biological Chemistry · 2002 · 175 citations · Full text